The study showed a trend toward higher composite all-cause mortality and amputations in the paclitaxel DCB group compared with PTA but this difference did not reach statistical significance (35.2 vs. 25.2%, P = 0.064).
← all excerpts
Comprehensive Assessment of Current Management Strategies for Patients With Diabetes and Chronic Limb-Threatening Ischemia.
1
—
—